Drug Profile
Apixaban - Bristol-Myers Squibb/Pfizer
Alternative Names: BMS-562247; BMS-562247-01; EliquisLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Massachusetts General Hospital; Pfizer
- Class 2 ring heterocyclic compounds; Amides; Anticoagulants; Antithrombotics; Cardiovascular therapies; Lactams; Phenyl ethers; Pyrazoles; Pyridones; Small molecules; Vascular disorder therapies
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
- Phase III Acute coronary syndromes
- Phase II Heparin-induced thrombocytopenia and thrombosis syndrome
Most Recent Events
- 31 Jul 2022 Bristol-Myers Squibb completes enrolment in the phase III AXADIA trial in Stroke and Thromboembolism (in patients with Atrial fibrillation and End-Stage Kidney Disease) in Germany (PO) (NCT02933697)
- 24 Feb 2022 Phase-III clinical trials in Thromboembolism (In adolescents, In children, In infants, Prevention) in USA (PO) (Bristol Myers Squibb pipeline, February 2022)
- 11 Jan 2022 Bristol-Myers Squibb initiates an expanded access program of Apixaban in Thromboembolism (In infants, In neonates, In children, In adolescents, Prevention)(NCT05187286)